Results: Over a 5-year period, a total of 298,105 patients underwent coronary angiography (CAG) and 176,166 patients underwent percutaneous coronary intervention (PCI). Diagnosis was acute coronary syndrome (ACS) in 22%, stable angina or silent ischemia in 23% and atypical chest pain in 9% of cases. Normal coronary arteries or not significant coronary lesions were found in 26% of patients. Radial access was increasingly used over the years regardless of the indication. The average number of PCI per procedure was 1.5±0.7 (range from 1.3±0.7 to 1.5±0.7) and those of stents per procedure were 1.5±0.8 (range from 1.5±0.8 to 1.6±0.8). Drug-eluting stents (DES) were used in 45% (range from 34 to 62%).
Clopidogrel low response and correlation between the different tests: light transmission aggregometry, Verify ow-P2Y12 and VASP.
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Methods:
In this prospective study, clopidogrel response was assessed in 100 consecutive patients. All patients were tested between 18h and 24h after a 600mg clopidogrel loading dose using 3 different tests: light transmission aggregometry with 10 µmol ADP (LTA, results expressed as platelet inhibition percentage), VerifyNow-P2Y12 (VN, results expressed as PRU) and vasodilatator stimulated phosphoprotein (VASP, results expressed as IRP). Patients under chronic clopidogrel therapy were excluded.
Results:
The mean platelet inhibition percentage, PRU value and IRP value were 38.5±13% by LTA, 178±89 PRU by VN and 52±21% by VASP. When results were analyzed as continuous variables, there was a good correlation between the different tests: LTA/VN (R2=0,642, p<0,001), LTA/VASP (R2=0,409, p<0,001) and VN/VASP (R2=0,616, p<0,001). However, when results were analyzed as pre-specified cut-off points to define patients as "low or good responders" (according to the literature: 50% for LTA, 235 PRU for VN and 50% IRP for VASP), only 47% of the patients were defined as "good" or "low responders" by the 3 tests. Altogether, 33% of the patients were defined as "low responders" by only 1 test, 20% by 2 tests and only 16% by the 3 tests.
Conclusion: If the correlation between the different tests is good when results are analyzed as continuous variables, each individual is rarely (less than 50%) defined as "low or good responder" by all the 3 tests when recognized cut-off values are used. In that way, a sole test might not be sufficient to manage antiplatelet therapy in an individual patient.
022

Compared efficacy and safety of unfractionned heparins versus low-molecular-weight heparins in STEMI patients
Mohamed Majed Hassine, Wiem Selmi, Mejdi Ben Messaoud, Ismail Ghrissi, Fehmi Karoui, Amine Hdiji, Fatma Ben Amor, Sami Ouanes, Mehdi Khlif, Mohamed Ben Doudouh, Zohra Dridi, Fethi Betbout, Habib Gamra CHU Fattouma Bourguiba, Monastir, Cardiologie A, Monastir, Tunisie Background: Low-molecular-weight heparins have recently been introduced in the management of ST elevation myocardial infarction (STEMI) patients but evidence remains poor among specific populations particularly elderly and patients with renal dysfunction.
Objective: to compare the outcome (mortality and hemorrhage) between patients treated with unfractionned heparin (UFH) versus low-molecularweight heparins (LMWHs) in the whole population and among elderly and renal dysfunction patients.
Methods:
Patients admitted for STEMI between January 1995 and November 2011 were retrospectively enrolled in the MIRAMI (MonastIR Acute Myocardial Infarction) registry. We compared the outcome (mortality and hemorrhage) between patients who received UFH versus LMWHs in the global MIRAMI population, then among elderly (aged over 75 years) and renal dysfunction patients (defined by a creatinin level >130 µmol/l).
Résultats: UFH was more often used when thrombolysis was adopted as reperfusion therapy (80.6% vs 68.6% when primary angioplasty is adopted, p<0.001), when patients present with heart failure (p<0.001), among elderly (p<0.001) and in patients with renal dysfunction (p=0.002). High rates of prescription of UFH may be attributed to the enrollment of patients since 1995, before LMWHs introduction in clinical practice. Mortality was higher among patient treated with UFH. This difference was statistically significant in the global population (11.9% vs 3.1%, p<0.001), but there was no significant differences among elderly (22.3% and 13.3%, p=0.65) and in renal dysfunction patients (39% vs 20%, p=0.23). Use of LMWHs did not show an increase of hemorrhagic complications in the global population (p=0.118), among elderly (p=0.45) nor renal dysfunction patients (p=0.61).
Conclusion:
In the MIRAMI registry, LMWHs seemed to be at least as safe and effective as UFH in STEMI patients, even in elderly or renal dysfunction population.
ational observational study of diagnostic and interventional cardiac catheterization by the French Society of Cardiology (O ACI): results according to administrates regions (northern vs. southern)
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Background: The national observational study of diagnostic and interventional cardiac catheterization (ONACI) is a prospective multi-center registry
